Bilcare

Why is Bilcare Ltd falling/rising?

As of 10-Jun, Bilcare Ltd's stock price is at 61.61, reflecting a 1.03% decrease and significant underperformance compared to the Sensex. The stock has declined 14.45% over the past month and is trading below its moving averages, indicating a bearish trend and decreased investor confidence.

As of 10-Jun, Bilcare Ltd's stock price is falling, currently at 61.61, which reflects a decrease of 0.64 or 1.03%. The stock has underperformed against the benchmark Sensex, which has only declined by 0.49% over the same period. Over the past week, Bilcare's stock has dropped by 4.48%, and it has experienced a significant decline of 14.45% over the past month. Year-to-date, the stock is down by 22.67%, compared to a 13.19% drop in the Sensex.<BR><BR>Additionally, the stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. Investor participation has also decreased, with a delivery volume of 7.58k on June 9, which is down by 15.52% compared to the 5-day average. This decline in trading activity suggests a lack of confidence among investors, contributing to the stock's downward movement. Overall, these factors indicate that Bilcare Ltd's stock is currently experiencing a decline.

What does Bilcare do?

Bilcare Ltd is a research-based company specializing in manufacturing specialty pharmaceutical packaging barrier films, classified as a Micro Cap in the Healthcare Services industry. As of March 2026, it reported net sales of 188 Cr and a net profit of 13 Cr.

Overview:<BR>Bilcare Ltd is a research-based organization primarily engaged in manufacturing specialty pharmaceutical packaging barrier films, operating within the Healthcare Services industry and classified as a Micro Cap company.<BR><BR>History:<BR>Bilcare Ltd was incorporated in July 1987 as Bhandari Paper Products Pvt Ltd and transitioned to a public limited company on October 27, 1994. The company rebranded to BI Ltd in 2001 and adopted its current name, Bilcare Ltd, on October 1, 2003. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 188 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 13 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 148 Cr (Micro Cap) <BR><BR>Key Metrics:<BR>P/E: 73.00 <BR>Industry P/E: 18 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 3.13 <BR>Return on Equity: 1.01% <BR>Price to Book: 0.75 <BR><BR>Contact Details:<BR>Address: 1028 Shiroli Village, Taluka Khed Rajgurunagar Pune Maharashtra : 410505 <BR>Tel: 91-02135-304200/204201 <BR>Email: investors@bilcare.com <BR>Website: http://www.bilcare.com

Which are the latest news on Bilcare?

How big is Bilcare?

As of 10th June, Bilcare Ltd has a market capitalization of 148.00 Cr and reported net sales of 733.54 Cr, with a loss of 1.82 Cr over the latest four quarters.

As of 10th June, Bilcare Ltd has a market capitalization of 148.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Bilcare reported net sales of 733.54 Cr. However, the company experienced a loss of 1.82 Cr during the same period.<BR><BR>The latest annual reporting period for Bilcare is March 2025, with shareholder's funds amounting to 469.04 Cr and total assets valued at 1,416.88 Cr.

Should I buy, sell or hold Bilcare Ltd?

Are Bilcare Ltd latest results good or bad?

Bilcare Ltd's latest results show a strong quarter-on-quarter profit increase of 1278.35% and a 3.50% rise in net sales, but year-on-year performance reveals a 23.95% profit decline and operational challenges, including high debt levels, raising concerns about sustainability. Overall, while there are positive signs, significant risks remain.

Bilcare Ltd's latest results present a mixed picture. On one hand, the company reported a significant quarter-on-quarter increase in consolidated net profit of ₹13.37 crores for Q4 FY26, which is an impressive rise of 1278.35%. Additionally, net sales grew by 3.50% from the previous quarter, reaching ₹187.66 crores, and the operating margin improved to 9.02%, the highest in eight quarters.<BR><BR>However, when looking at the year-on-year performance, there are notable declines. The net profit decreased by 23.95% compared to the same quarter last year, and net sales fell by 3.28% from ₹194.03 crores in Q4 FY25. This suggests that while there has been a recovery from previous losses, the overall trend remains concerning, particularly with the company facing high debt levels and a negative return on equity of -3.67%.<BR><BR>Moreover, the reliance on other income to boost profits raises questions about the sustainability of these results. The company's operational challenges, including a high debt-to-EBITDA ratio and a lack of institutional investor confidence, further complicate the outlook.<BR><BR>In summary, while the quarterly results show some positive momentum, the underlying fundamentals indicate significant risks and challenges that may overshadow these improvements.

How has been the historical performance of Bilcare?

Bilcare's historical performance has been volatile, with net sales declining from 2,997.01 Cr in Mar'19 to 788.04 Cr in Mar'25, and significant losses in profit before tax and profit after tax in recent years. However, there are signs of recovery in cash flow, which turned positive at 84.00 Cr in Mar'25.

Answer:<BR>The historical performance of Bilcare shows significant fluctuations in its financial metrics over the years.<BR><BR>Breakdown:<BR>Bilcare's net sales have seen a decline from 2,997.01 Cr in Mar'19 to 788.04 Cr in Mar'25, with a notable drop in Mar'23 at 981.62 Cr and a slight recovery in Mar'24 at 747.18 Cr. Total operating income followed a similar trend, decreasing from 2,997.01 Cr in Mar'19 to 788.04 Cr in Mar'25. The raw material cost has also decreased from 1,631.68 Cr in Mar'19 to 535.89 Cr in Mar'25, while employee costs have increased slightly from 71.87 Cr in Mar'24 to 81.07 Cr in Mar'25. Operating profit (PBDIT) has fluctuated, peaking at 142.31 Cr in Mar'20 and dropping to 63.09 Cr in Mar'25. The profit before tax has been negative in recent years, with -71.34 Cr in Mar'25 compared to -432.52 Cr in Mar'19. The profit after tax also reflects this trend, showing a loss of -56.16 Cr in Mar'25, down from a profit of 50.21 Cr in Mar'23. Total liabilities decreased from 1,593.39 Cr in Mar'23 to 1,416.88 Cr in Mar'25, while total assets also declined from 1,593.39 Cr to 1,416.88 Cr in the same period. The cash flow from operating activities turned positive at 84.00 Cr in Mar'25, contrasting with negative figures in previous years. Overall, Bilcare's financial performance has been marked by volatility, with significant losses in recent years but some signs of recovery in cash flow.

When is the next results date for Bilcare?

The next results date for Bilcare is 14 November 2025.

The next results date for Bilcare is scheduled for 14 November 2025.

Who are the top shareholders of the Bilcare?

The top shareholders of Bilcare are Mohan Harakchand Bhandari with 24.87%, Monument Pte Limited at 16.44%, and individual investors collectively holding 44.68%. There are no mutual funds invested, and foreign institutional investors hold only 0.04%.

The top shareholders of Bilcare include Mohan Harakchand Bhandari, who holds the highest promoter stake at 24.87%. The next significant shareholder is Monument Pte Limited, with a holding of 16.44%. Additionally, individual investors collectively hold 44.68% of the shares. It's worth noting that there are no mutual funds currently holding shares in Bilcare, and foreign institutional investors (FIIs) hold a minimal stake of 0.04%.

Who are the peers of the Bilcare?

Bilcare's peers include 3B Blackbio, Sastasundar Ven., Prevest Denpro, One Global Serv, Nureca, Hemant Surgical, Take Solutions, Choksi Laborator, and Royal Sense. In terms of management risk, growth, and capital structure, Bilcare is rated Below Average compared to its peers, with a 1-year return of 27.98%.

Peers: The peers of Bilcare are 3B Blackbio, Sastasundar Ven., Prevest Denpro, One Global Serv, Nureca, Hemant Surgical, Take Solutions, Choksi Laborator, and Royal Sense.<BR><BR>Quality Snapshot: Excellent management risk is observed at One Global Serv and Hemant Surgical, while Average management risk is found at 3B Blackbio, Prevest Denpro, Nureca, and the rest. Below Average management risk is noted for Sastasundar Ven., Bilcare, Take Solutions, Choksi Laborator, and Royal Sense. Growth is Excellent at 3B Blackbio, One Global Serv, and Royal Sense, while Average growth is seen at Choksi Laborator, and Below Average growth is found at Sastasundar Ven., Prevest Denpro, Nureca, Hemant Surgical, Bilcare, Take Solutions, and the rest. Capital Structure is Excellent at 3B Blackbio, One Global Serv, Sastasundar Ven., Prevest Denpro, Nureca, Hemant Surgical, and Royal Sense, while Below Average capital structure is noted for Bilcare, Take Solutions, Choksi Laborator, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Choksi Laborator at 242.39%, while the lowest is Take Solutions at -52.91%. Bilcare's own 1-year return of 27.98% is significantly higher than Take Solutions but lower than Choksi Laborator. Additionally, the six-month return is negative for Nureca, Take Solutions, and Royal Sense.

Is Bilcare overvalued or undervalued?

As of May 28, 2024, Bilcare's valuation has shifted from expensive to risky, indicating it is overvalued with a PE ratio of -14.24, an EV to EBITDA of 19.08, and a Price to Book Value of 0.39, all of which highlight significant profitability challenges compared to its healthcare peers, despite a strong 36.03% return over the past year that lags behind the Sensex's 7.60% return.

As of 28 May 2024, the valuation grade for Bilcare has moved from expensive to risky, indicating a shift in perception regarding its financial health and market position. The company appears to be overvalued at this time. Key ratios reflect this concern, with a PE Ratio of -14.24, an EV to EBITDA of 19.08, and a Price to Book Value of 0.39, all suggesting significant challenges in profitability and valuation.<BR><BR>When compared to peers in the healthcare services industry, Bilcare's metrics stand out negatively; for instance, its PE ratio is substantially lower than the industry average, while its EV to EBITDA ratio is considerably high. Notably, companies like [insert peer name] have more favorable ratios, reinforcing the notion that Bilcare is not performing well relative to its competitors. Additionally, while Bilcare has shown strong returns over the past year at 36.03%, this is contrasted by its recent performance, which has lagged behind the Sensex return of 7.60% over the same period, further emphasizing the risks associated with its current valuation.

What is the technical trend for Bilcare?

As of June 3, 2025, Bilcare's trend is mildly bullish, supported by daily moving averages and Bollinger Bands, despite mixed signals from the MACD and RSI.

As of 3 June 2025, the technical trend for Bilcare has changed from bullish to mildly bullish. The weekly MACD indicates a mildly bearish stance, while the monthly MACD remains bullish, suggesting mixed signals. The RSI shows no signal on the weekly chart and is bearish on the monthly, indicating potential weakness. Bollinger Bands are mildly bullish on both weekly and monthly time frames, supporting a positive outlook. Daily moving averages are also mildly bullish, reinforcing the current trend. However, the Dow Theory presents a mildly bullish view weekly but is bearish monthly, adding to the mixed sentiment. Overall, the current stance is mildly bullish, driven primarily by the daily moving averages and Bollinger Bands, despite some bearish signals in the MACD and RSI.

Who are in the management team of Bilcare?

As of March 2022, the management team of Bilcare includes Shreyans Bhandari (Chairman & Managing Director), Kavita Bhansali (Executive Director), and several independent directors, including Rajesh Devene, Madhuri Vaidya, Ashwani Singh, Diksha Tamar, and Vijesh Mehra, along with Prabhavi Mungee as Company Secretary & Compliance Officer.

As of March 2022, the management team of Bilcare includes the following individuals:<BR><BR>1. Rajesh Shankarrao Devene - Independent Director<BR>2. Prabhavi Mungee - Company Secretary & Compliance Officer<BR>3. Madhuri Vaidya - Independent Director<BR>4. Ashwani Singh - Non-Executive & Independent Director<BR>5. Diksha Tamar - Independent Director<BR>6. Vijesh Mehra - Independent Director<BR>7. Shreyans Bhandari - Chairman & Managing Director<BR>8. Kavita Bhansali - Executive Director<BR><BR>These members play various roles within the company, contributing to its governance and operational management.

Has Bilcare declared dividend?

Bilcare Ltd has declared a 20% dividend, amounting to ₹2 per share, with an ex-date of September 20, 2012. However, the dividend yield is 0%, as there have been no dividends in recent periods, despite significant price appreciation over the last five years.

Bilcare Ltd has declared a 20% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 20%<BR>- Amount per share: 2<BR>- Ex-date: 20 Sep 12<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>Over the 6-month period, the price return was 37.02%, the dividend return was 0%, resulting in a total return of 37.02%.<BR><BR>In the 1-year period, the price return was 33.58%, the dividend return was 0%, leading to a total return of 33.58%.<BR><BR>For the 2-year period, the price return was 40.86%, the dividend return was 0%, which culminated in a total return of 40.86%.<BR><BR>During the 3-year period, the price return was 14.24%, the dividend return was 0%, resulting in a total return of 14.24%.<BR><BR>In the 4-year period, the price return was 39.29%, the dividend return was 0%, leading to a total return of 39.29%.<BR><BR>Over the 5-year period, the price return was 167.02%, the dividend return was 0%, culminating in a total return of 167.02%.<BR><BR>Overall, while Bilcare Ltd has declared a dividend, the dividend yield remains at 0%, indicating that the company has not provided dividends in recent periods. However, the total returns over various periods show significant price appreciation, particularly over the 5-year period.